Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Cisplatin + Fluorouracil
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cisplatin Platinol CDDP Chemotherapy - Platinum 7 Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).
Fluorouracil Adrucil 5-FU|5-Fluorouracil Chemotherapy - Antimetabolite 14 Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04210115 Phase III Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) Active, not recruiting USA | TUR | ROU | ITA | HUN | GBR | FRA | EST | DNK | DEU | CZE | CAN | BRA | BEL | ARG 12
NCT03189719 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) Completed USA | TUR | ROU | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUS | ARG 14
NCT06019130 Phase II Cisplatin + Fluorouracil Cisplatin + Gemcitabine Nivolumab Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo) Recruiting DEU 0
NCT02494583 Phase III Capecitabine Cisplatin + Fluorouracil Pembrolizumab Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed 0
NCT07026474 Phase III Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Pembrolizumab Cisplatin + Fluorouracil Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS>/=1) HNSCC (RePaIr-HN) Recruiting DEU 0
NCT02205047 Phase II Capecitabine + Cisplatin Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Capecitabine + Cisplatin + Pertuzumab + Trastuzumab Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION) Completed NOR | NLD | ITA | GBR | FRA | EST | ESP | DEU | CHE | BEL 3
NCT03221426 Phase III Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed USA | POL | LVA | LTU | ITA | ISR | GBR | FRA | EST | DEU | CAN | BRA | BEL 11
NCT03777657 Phase III Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed USA | TUR | POL | ITA | GBR | FRA | ESP 6
NCT04747054 Phase III Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) Recruiting FRA 0
NCT04550260 Phase III Cisplatin + Fluorouracil Capecitabine + Cisplatin Capecitabine + Cisplatin + Durvalumab Cisplatin + Durvalumab + Fluorouracil Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN) Active, not recruiting USA | TUR | POL | FRA | ESP | CAN | BRA | BEL 8
NCT03748134 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Sintilimab Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Sintilimab Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15) Completed USA | HUN | FRA | ESP | BEL | AUS 1
NCT03675737 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed USA | TUR | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG 14
NCT03143153 Phase III Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) Completed USA | TUR | ROU | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | AUT | AUS | ARG 12
NCT00588770 Phase III Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 2
NCT03281369 Phase Ib/II Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Completed USA | ISR | GBR | ESP | AUS 2
NCT02051868 Phase II Carboplatin + Paclitaxel Cisplatin + Fluorouracil International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT) Unknown status USA | GBR | AUS 0
NCT05661188 Phase II Atezolizumab + Tiragolumab Cisplatin + Fluorouracil Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS) Recruiting ESP 0
NCT03727061 Phase II Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Terminated USA 0


Additional content available in Icon for CKB-BoostCKB BOOST